Publications in scientific journals

Lachaine J, Sikirica V, Mathurin K. Is adjunctive pharmacotherapy in attention-decifit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD. BMC Psychiatry, 2016;16:11;DOI: 10.1186/s12888-016-0708-x.

Zhang E, Wartelle-Bladou C, Lepanto L, Lachaine J, Cloutier G, Tang A. Cost-utility analysis of nonalcoholic steatohepatitis screening. European Radiology, 2015;25:3282-3294.

Beauchemin C, Johnston JB, Lapierre M, Aissa F,Lachaine J. Relation between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis. Current Oncology, 2015;DOI:10.3747/co.22.2119.

Lachaine J, Lapierre ME, Abdalla N, Rouleau A, Stip E. Impact of switching to long-acting injectable antipsychotics on health services use in the treatment of schizophrenia. Canadian Journal of Psychiatry, 2015;60(3 Suppl 2):S40-S47.

Lachaine J, Mathurin K, Barakat S, Couban S. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada. European Journal of Haematology, 2015;DOI:10.1111/ejh.12475.

Bartlett G, Rahimzadeh V, Longo C, Orlando LA, Dawes M, Lachaine J, Bochud M, Paccaud F, Bergman H, Crimi L, Issa AM. The future of genomic testing in primary care: the changing face of personalized medicine. Personalized Medicine, 2014;11(5):477-486.

Lachaine J, De G, Sikirica V, van Stralen J, Hodgkins P, Yang H, Heroux J, Ben Amor L. Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in Quebec. Canadian Journal of Psychiatry, 2014 Nov;59(11):597-608.

Archambault PM, van de Belt TH, Faber MJ, Plaisance A, Kuziemsky C, Gagnon MP, Turgeon A, Aubin K, Poitras J, Horsley T, Lapointe J, Brand K, Witteman W, Lachaine J, Légaré F. Collaborative writing applications in healthcare: effects on professional practice and healthcare outcomes. Cochrane Database of Systematic Reviews, 2014, Issue 11.

Lachaine J, Mathurin K, Barakat S, Schuh A. Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute promyelocytic leukaemia in Canada. Hematological Oncology, 2014 Nov;DOI:10.1002/hon.2176.

Ben Amor L, Sikirica V, Cloutier M, Lachaine J, Guerin A, Carter V, Hodgkins P, van Stralen J. Combination and switching of stimulants in children and adolescents with attention deficit/hyperactivity disorder in Quebec. Journal of the Canadian Academy of Child and Adolescent Psychiatry (JCACAP), 2014 Sep;23(3):157-166.

Lachaine J, Beauchemin C, Mathurin K, Gilbert D, Beillat M. Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada. Journal of Medical Economics, 2014 Apr;17(4):296-304.

Lachaine J, Beauchemin C, Mathurin K, Gilbert D, Beillat M. Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada. BMC Psychiatry, 2014 Jan 22;14(1):16.

Levesque A, Lachaine J, Bissonnette R. Risk of myocardial infarction in Canadian patients with psoriasis: a retrospective cohort study. Journal of Cutaneous Medicine and Surgery, 2013 Nov-Dec;17(6):398-403.

Touchon J, Lachaine J, Beauchemin C, Granghaud A, Rive B, Bineau S. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France. The European Journal of Health Economics, 2013 Aug 9.

Lachaine J, Beauchemin C, Crochard A, Bineau S. The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: analysis using the Régie de l’assurance maladie du Québec database. Canadian Journal of Psychiatry, 2013 Apr;58(4):195-200.

Lachaine J, Yen L, Beauchemin C, Hodgkins P. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. BMC Gastroenterology, 2013 Jan 30;13:23.

Lachaine J, Beauchemin C, Sasane R, Hodgkins PS. Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective. PostGraduate Medicine, 2012 May;124(3):139-48.

Lachaine J, Beauchemin C. Economic evaluation of dexmedetomidine relative to midazolam for sedation in the intensive care unit. Canadian Journal of Hospital Pharmacy, 2012 Mar;65(2):103-10.

Lachaine J, Beauchemin C, Legault M, Bineau S. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease. Canadian Journal of Psychiatry, 2011 Oct;56(10):596-604.

Lachaine J, Beauchemin C, Ramos E. Use, tolerability and compliance of spironolactone in the treatment of heart failure. BMC Clinical Pharmacology, 2011 May;11(4).

Lachaine J, Beauchemin C, Landry PA. Clinical and economic characteristics of patients with fibromyalgia syndrome. Clinical Journal of Pain, 2010 May;26(4):284-90.

Lachaine J, Petrella R, Merikle E, Ali F. Choices, persistence and adherence to antihypertensive agents: evidence from RAMQ data. Canadian Journal of Cardiology, 2008 Apr;24(4):269-73.

Lachaine J, Hodge WG, Steffensen I, Murray C, Barnes D, Foerster V, Ducruet T, Mensinkai T. Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis. Canadian Journal of Ophathalmology, 2008 Feb;43(1):33-41.

Hodge WG, Lachaine J, Steffensen I, Murray C, Barnes D, Foerster V, Ducruet T, Morrison A. The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review. British Journal of Ophthalmology, 2008 Jan;92(1):7-12.

Lachaine J, Merikle E, Tarride JE, Montpetit M, Rinfret S. A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets. Clinical Therapeutics, 2007 Mar;29(3):519-28.

Lachaine J, Gordon A, Choinière M, Collet JP, Dion D, Tarride JE. Painful neuropathic disorders: an analysis of the Régie de l’assurance maladie du Québec database. Pain Research & Management, 2007 Spring;12(1):31-7.

Lachaine J. Therapeutic options for the prevention and treatment of postoperative nausea and vomiting: a pharmacoeconomic review. Pharmacoeconomics, 2006;24(10):955-70.

Lachaine J, Rinfret S, Merikle EP, Tarride JE. Persistence and adherence to cholesterol lowering agents: evidence from the Régie de l’assurance maladie du Québec data. American Heart Journal, 2006 Jul;152(1):164-9.

Lachaine J. Le fardeau économique de la douleur et de son soulagement. Frontières, Printemps 2005:89-91.

Lachaine J. Chemotherapy-induced emesis: treatment options. Hospital Pharmacy Europe, Summer 2003:2-3.